EUVIMEDEUVIMED entdecken
Leserbrief

Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants

William J Muller iD, Shabir A Madhi iD, Beatriz Seoane Nuñez, Manuel Baca Cots, Miroslava Bosheva, Ron Dagan iD, Laura L Hammitt, Conrado J Llapur, Jose M Novoa, Xavier Saez Llorens, Amy Grenham, Elizabeth J Kelly und 6 weitere

New England Journal of Medicine · 20.04.2023 · 388 (16) · 1533-1534

DOI: 10.1056/nejmc2214773 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 20.04.2023. Verfasst von William J Muller und 17 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University, Chicago, IL. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antiviral Agents, Infant, Premature, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 254-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: AstraZeneca, Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntiviral AgentsInfant, PrematureRespiratory Syncytial Virus InfectionsInfant, Newborn, DiseasesHumansInfantInfant, NewbornHospitalizationPalivizumabTerm Birth

Substanzen

Antibodies, Monoclonal, HumanizedAntiviral AgentsnirsevimabPalivizumab

Autor:innen und Institutionen

  • Northwestern University, Chicago, IL.
  • University of the Witwatersrand, Johannesburg, South Africa.
  • AstraZeneca, Barcelona, Spain.
  • Quirónsalud Málaga Hospital, Malaga, Spain.
  • St. George Medical University, Plovdiv, Bulgaria.
  • Ben-Gurion University of the Negev, Beer-Sheva, Israel.

ORCID-Profile: William J Muller, Shabir A Madhi, Ron Dagan

Förderung

  • AstraZeneca
  • Sanofi

Zitieren

APA

Muller, W. J., Madhi, S. A., Seoane Nuñez, B., Baca Cots, M., Bosheva, M., Dagan, R., Hammitt, L. L., Llapur, C. J., Novoa, J. M., Saez Llorens, X., Grenham, A., Kelly, E. J., Mankad, V. S., Shroff, M., Takas, T., Leach, A., Villafana, T., & MELODY Study Group (2023). Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. New England Journal of Medicine, 388(16), 1533-1534. https://doi.org/10.1056/nejmc2214773

Vancouver

Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, et al. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. New England Journal of Medicine. 2023;388(16):1533-1534. doi:10.1056/nejmc2214773

BibTeX
@article{Muller2023,
  author = {Muller, William J and Madhi, Shabir A and Seoane Nuñez, Beatriz and Baca Cots, Manuel and Bosheva, Miroslava and Dagan, Ron and Hammitt, Laura L and Llapur, Conrado J and Novoa, Jose M and Saez Llorens, Xavier and Grenham, Amy and Kelly, Elizabeth J and Mankad, Vaishali S and Shroff, Manish and Takas, Therese and Leach, Amanda and Villafana, Tonya and MELODY Study Group, MELODY Study Group},
  title = {Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {16},
  pages = {1533--1534},
  doi = {10.1056/nejmc2214773}
}
Kostenlos starten →